TEL AVIV, Israel & SAN DIEGO--(BUSINESS WIRE)-- VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced data demonstrating VB-201 was found to be effective in attenuating inflammatory bowel disease (IBD) in preclinical models. VB-201 is a first-in-class, orally available disease-modifying agent selected from a series of proprietary oxidized phospholipid analogs pioneered by VBL in the Lecinoxoid molecular class. The results were presented today during a poster presentation at Digestive Disease Week (DDW) 2012 by Eyal Breitbart, Ph.D., vice president of research at VBL.
